Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P070014/S067

LIFESTENT FLEXSTAR & FLEXSTAR XL VASCULAR STENT SYSTEM

Bard Peripheral Vascular, Inc. · Decision date Mar 10, 2026

FDA DECISIONP070014/S067

What did the FDA approve?

FDA records P070014/S067 as a supplement to PMA P070014, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Mar 10, 2026.

FDA approval order statement

approval for modifications to the packaging of the LifeStent and LifeStent XL Vascular Stent System.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Mar 10, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P070014/S067
Regulatory pathway
PMA supplement
Product code
NIP
Decision code
APPR
Decision date
Mar 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: STENT, SUPERFICIAL FEMORAL ARTERY.

Product code
NIP
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P070014/S067 received

    Application receipt date recorded by FDA.

  2. P070014/S066 · Related supplement

    LifeStent Vascular Stent Systems

  3. P070014/S067 · FDA decision

    Real-Time Process

  4. P070014/S068 · Related supplement

    LifeStent 5F Vascular Stent System

  5. P070014/S069 · Related supplement

    LifeStent 5F Vascular Stent Systems

Timeline entries are records held by MedtechLedger for P070014. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P070014

Product / regulatory recordCompanyPathwayDecision dateSource
Bard Peripheral Vascular, Inc.PMA supplementDec 16, 2025FDA
Bard Peripheral Vascular, Inc.PMA supplementMay 15, 2026FDA
Bard Peripheral Vascular, Inc.PMA supplementJun 10, 2026FDA

Explore the linked device profile

Other records with product code NIP

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Bard Peripheral Vascular, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1415 W. 3rd St., Tempe, AZ, 85281

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records